Payment overview · 2025
General Payments
$3,934.60
133 reported records · 19 companies
Healthcare provider profile · identity verified
Dennis Trieu
Allopathic & Osteopathic Physicians|General Practice · LOS ANGELES, CA · NPI 1245862887
Verified facts
What the public records show
CMS Open Payments records show Dennis Trieu received $3,934.60 in general payments during 2025 across 133 reported records.
AstraZeneca Pharmaceuticals LP accounted for 18.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Airsupra, Creon, Farxiga, Jardiance, Kerendia, Linzess, Ozempic, Trelegy Ellipta, Voquezna, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Linzess by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AIRSUPRA as an associated drug or biological on 165148 records involving 56069 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Airsupra by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 210 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synjardy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Rybelsus by this doctor in 2024.
Phathom Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VOQUEZNA as an associated drug or biological on 90302 records involving 33442 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Voquezna by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $708.28 | 18.0% | 15 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $529.90 | 13.5% | 12 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $416.62 | 10.6% | 22 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $337.15 | 8.6% | 11 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $318.43 | 8.1% | 19 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $293.42 | 7.5% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $247.85 | 6.3% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $189.85 | 4.8% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $184.22 | 4.7% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $147.37 | 3.8% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $138.99 | 3.5% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $114.66 | 2.9% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $83.02 | 2.1% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $69.57 | 1.8% | 3 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.77 | 1.2% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $40.93 | 1.0% | 2 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $27.09 | 0.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.78 | 0.6% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.70 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,934.60 | 133 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $416.62 | 22 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $399.57 | 7 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $359.32 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $325.73 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $318.43 | 19 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $293.42 | 11 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $247.85 | 11 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $184.22 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $173.30 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $143.18 | 6 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $138.99 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $130.33 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $130.33 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $86.12 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $83.67 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $83.02 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.18 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $40.93 | 2 | 2025 |
Source payment records
|
|||||
| VOWST Normalized: vowst |
Biological | Aimmune Therapeutics, Inc. | $30.99 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.56 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AIRSUPRA airsupra |
2025 | Airsupra | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| CREON creon |
2025 | Creon | 2024 | 66 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 210 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 97 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 65 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 160 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 27 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 100 | exact normalized | Medicare Part D |
| VOQUEZNA voquezna |
2025 | Voquezna | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 24 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
66 | 38 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
160 | 65 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
24 | 17 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
16 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | AIRSUPRA open payments reported associated product |
CMS Open Payments — General Payments 165148 supporting records · 56069 recipient NPIs · example record 1206131344 |
Airsupra · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
210 | 55 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
65 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
100 | 35 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
160 | 65 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
27 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
82 | 26 |
| Phathom Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | VOQUEZNA open payments reported associated product |
CMS Open Payments — General Payments 90302 supporting records · 33442 recipient NPIs · example record 1219216983 |
Voquezna · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 800 | 257 |
| Losartan Potassium | Losartan Potassium | 707 | 219 |
| Montelukast Sodium | Montelukast Sodium | 612 | 248 |
| Amlodipine Besylate | Amlodipine Besylate | 556 | 178 |
| Celecoxib | Celecoxib | 475 | 221 |
| Omeprazole | Omeprazole | 361 | 147 |
| Gabapentin | Gabapentin | 355 | 159 |
| Simvastatin | Simvastatin | 351 | 105 |
| Vascepa | Icosapent Ethyl | 317 | 83 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 277 | 88 |
| Tamsulosin Hcl | Tamsulosin Hcl | 240 | 77 |
| Metformin Hcl | Metformin Hcl | 229 | 67 |
| Alendronate Sodium | Alendronate Sodium | 228 | 79 |
| Azelastine Hcl | Azelastine Hcl | 217 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 216 | 63 |
| Farxiga | Dapagliflozin Propanediol | 210 | 55 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 207 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 197 | 62 |
| Pioglitazone Hcl | Pioglitazone Hcl | 188 | 48 |
| Baclofen | Baclofen | 187 | 103 |
| Pantoprazole Sodium | Pantoprazole Sodium | 179 | 82 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 58 |
| Prednisone | Prednisone | 172 | 143 |
| Allopurinol | Allopurinol | 162 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 45 |
| Linzess | Linaclotide | 160 | 65 |
| Metformin Hcl Er | Metformin Hcl | 159 | 44 |
| Diclofenac Sodium | Diclofenac Sodium | 156 | 95 |
| Icosapent Ethyl | Icosapent Ethyl | 145 | 72 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 140 | 76 |
| Januvia | Sitagliptin Phosphate | 138 | 36 |
| Finasteride | Finasteride | 134 | 35 |
| Meclizine Hcl | Meclizine Hcl | 133 | 77 |
| Amoxicillin | Amoxicillin | 129 | 118 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 119 | 55 |
| Trazodone Hcl | Trazodone Hcl | 112 | 57 |
| Azithromycin | Azithromycin | 108 | 102 |
| Ropinirole Hcl | Ropinirole Hcl | 108 | 36 |
| Fluocinonide | Fluocinonide | 106 | 54 |
| Raloxifene Hcl | Raloxifene Hcl | 102 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 100 | 35 |
| Ibuprofen | Ibuprofen | 99 | 80 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 99 | 29 |
| Jardiance | Empagliflozin | 97 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 95 | 51 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 89 | 60 |
| Ammonium Lactate | Ammonium Lactate | 87 | 49 |
| Nifedipine Er | Nifedipine | 85 | 19 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 84 | 56 |
| Cephalexin | Cephalexin | 83 | 75 |
| Dutasteride | Dutasteride | 83 | 21 |
| Eliquis | Apixaban | 83 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 44 |
| Rybelsus | Semaglutide | 82 | 26 |
| Tradjenta | Linagliptin | 81 | 16 |
| Atenolol | Atenolol | 80 | 25 |
| Potassium Chloride | Potassium Chloride | 80 | 32 |
| Meloxicam | Meloxicam | 79 | 29 |
| Famotidine | Famotidine | 78 | 26 |
| Furosemide | Furosemide | 77 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 73 | 19 |
| Carvedilol | Carvedilol | 72 | 20 |
| Donepezil Hcl | Donepezil Hcl | 71 | 27 |
| Nebivolol Hcl | Nebivolol Hcl | 71 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 67 | 22 |
| Mupirocin | Mupirocin | 67 | 51 |
| Creon | Lipase/Protease/Amylase | 66 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 66 | 24 |
| Kerendia | Finerenone | 65 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 64 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 22 |
| Dexlansoprazole Dr | Dexlansoprazole | 61 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 18 |
| Lidocaine | Lidocaine | 59 | 21 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 53 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 55 | 17 |
| Erythromycin | Erythromycin Base | 55 | 23 |
| Synjardy | Empagliflozin/Metformin Hcl | 53 | 12 |
| Fluocinonide-E | Fluocinonide/Emollient Base | 52 | 32 |
| Proctozone-Hc | Hydrocortisone | 52 | 26 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 49 | 19 |
| Propranolol Hcl | Propranolol Hcl | 49 | 24 |
| Glipizide | Glipizide | 48 | 14 |
| Valsartan | Valsartan | 47 | 12 |
| Lisinopril | Lisinopril | 46 | 12 |
| Hydrocortisone | Hydrocortisone | 45 | 33 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 45 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 44 | suppressed |
| Mirtazapine | Mirtazapine | 44 | 21 |
| Naproxen | Naproxen | 44 | 31 |
| Glimepiride | Glimepiride | 43 | 18 |
| Clobetasol Propionate | Clobetasol Propionate | 42 | 19 |
| Labetalol Hcl | Labetalol Hcl | 42 | suppressed |
| Nexletol | Bempedoic Acid | 42 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 41 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | 27 |
| Lansoprazole | Lansoprazole | 39 | 20 |
| Telmisartan | Telmisartan | 37 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 13 |
| Ezetimibe | Ezetimibe | 35 | 14 |
| Ketoconazole | Ketoconazole | 35 | 23 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 34 | 11 |
| Myrbetriq | Mirabegron | 34 | 13 |
| Cyclosporine | Cyclosporine | 33 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | 13 |
| Brilinta | Ticagrelor | 32 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 31 | 22 |
| Fenofibrate | Fenofibrate | 31 | 15 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 30 | 23 |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 27 | 15 |
| Irbesartan | Irbesartan | 27 | suppressed |
| Metronidazole | Metronidazole | 27 | 27 |
| Ozempic | Semaglutide | 27 | 11 |
| Vemlidy | Tenofovir Alafenamide | 27 | suppressed |
| Pregabalin | Pregabalin | 26 | 12 |
| Procto-Med Hc | Hydrocortisone | 26 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 23 |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | 17 |
| Loperamide | Loperamide Hcl | 24 | 22 |
| Nitroglycerin | Nitroglycerin | 24 | 18 |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 24 | 17 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 23 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Selenium Sulfide | Selenium Sulfide | 22 | 15 |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Lactulose | Lactulose | 21 | 15 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 20 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 18 | 11 |
| Clonidine | Clonidine | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Ssd | Silver Sulfadiazine | 18 | 13 |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 17 | 17 |
| Levofloxacin | Levofloxacin | 17 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | 16 |
| Benzonatate | Benzonatate | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Prolia | Denosumab | 16 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | 14 |
| Airsupra | Albuterol Sulfate/Budesonide | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Roflumilast | Roflumilast | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 14 | 11 |
| Colchicine | Colchicine | 14 | suppressed |
| Entecavir | Entecavir | 14 | suppressed |
| Voquezna | Vonoprazan Fumarate | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 13 |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 12 |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 11 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Trulicity | Dulaglutide | 11 | suppressed |
| Ursodiol | Ursodiol | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,934.60 · 133 records | AstraZeneca Pharmaceuticals LP | AFREZZA, AIRSUPRA, BREZTRI, CREON, Cologuard Collection Kit, EVENITY, FARXIGA, JARDIANCE, Kerendia, LINZESS, MOUNJARO, OTEZLA, Ozempic, PYRUKYND, REPATHA, TRELEGY ELLIPTA, Tymlos, VOQUEZNA, VOWST, XIFAXAN, ZENPEP, ZEPBOUND, ZORYVE | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Airsupra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error